Vol.67 No.4 July 2019
Survey of the susceptibility to daptomycin of methicillin-resistant Staphylococcus aureus (MRSA) isolated from April 2015 to April 2017 (additional report) -results of the special drug use survey
1)Medical Affairs, MSD K.K., KITANOMARU SQUARE, 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, Japan
2)Pharmacovigilance, MSD K.K.
Abstract
The antibacterial activities of daptomycin, vancomycin, teicoplanin, linezolid, and arbekacin against methicillin-resistant Staphylococcus aureus (MRSA) isolated from skin and soft tissue specimens from April 2015 to April 2017 (100 and 200 MRSA strains for each year, respectively) were tested by methods recommended by the Clinical and Laboratory Standards Institute. By including the results of the susceptibility of MRSA to DAP between April 2012 and April 2015 (Japanese Journal of Chemotherapy 2017; 65: 821-4), the yearly changes during the 5-year period of 2012-2016 were summarized. The MIC90 values of DAP for all the blood-, skin-, and soft tissue-derived MRSA strains collected in 2015 and 2016 were 0.5 μg/mL, thus showing that all isolates were susceptible to DAP. The geometric mean of the MICs of DAP also showed no changes in both between the two years. Comparison with the results obtained between 2012 and 2014 also revealed few changes in the MIC90 and geometric mean values. Furthermore, no isolates were found to be resistant to any of the control drugs, and no differences in the geometric mean MICs were noted among the years. These results demonstrated that MRSA strains are highly susceptible to DAP and that the susceptibility levels remained relatively unchanged during the 5-year-period of 2012-2016 in Japan.
Key word
daptomycin, vancomycin, MRSA, surveillance
Received
November 27, 2018
Accepted
February 26, 2019
Jpn. J. Chemother. 67 (4): 488-492, 2019
